

Efficacy and safety of entecavir compared to lamivudine in nucleoside-naïve patients with chronic hepatitis B: a randomized double-blind trial in China

Guangbi Yao · Chengwei Chen · Weilun Lu · Hong Ren · Deming Tan · Yuming Wang · Daozheng Xu · Zhengrong Jiang · Jessica Liu · Dong Xu · Laurie MacDonald · for the AI463023 Study Group

Published online: 12 January 2008
© Asian Pacific Association for the Study of the Liver 2008

Erratum to: *Hepatol Int* DOI 10.1007/s12072-007-9009-2

In the online and print edition of this article, the following statement appears incorrectly in the discussion section:

In HBeAg-positive patients, entecavir showed superiority over lamivudine for HBV DNA <300 (90% vs. 72%) and ALT normalization (78% vs. 71%).

The correct statement is as follows:

In HBeAg-negative patients, entecavir showed superiority over lamivudine for HBV DNA <300 (90% vs. 72%) and ALT normalization (78% vs. 71%).

The online version of the original article can be found under doi: [10.1007/s12072-007-9009-2](https://doi.org/10.1007/s12072-007-9009-2).

G. Yao (✉)
Shanghai Jing An Qu Central Hospital, No. 259 Xikang Rd,
Shanghai 200040, China
e-mail: yaogb@yahoo.com.cn

C. Chen
Shanghai Liver Disease Center of Nangjing Military Command,
Shanghai, China

W. Lu
No. 3 Hospital Affiliated to Sun Yat-Sen University, Guangzhou,
China

H. Ren
No. 2 Hospital Affiliated to Chongqing Medical University,
Chongqing, China

D. Tan
Infectious Disease Department of Xiang Ya Hospital, Changsha,
China

Y. Wang
Xinan Hospital, Chongqing, China

D. Xu
Beijing Di Tan Hospital, Beijing, China

Z. Jiang
Shanghai Roche Pharmaceutical Company, Shanghai, China

J. Liu
Bristol-Myers Squibb Company, Pharmaceutical Research
Institution, Braine-l'Alleud, Belgium

D. Xu · L. MacDonald
Bristol-Myers Squibb Company, Wallingford, CT, USA

for the AI463023 Study Group
Shanghai, China